We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
Read MoreHide Full Article
Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) reported break-even earnings for the second quarter of 2024 compared with the Zacks Consensus Estimate of earnings of 17 cents per share. The company had recorded adjusted earnings of 31 cents per share in the year-ago quarter.
Total revenues in the second quarter were $94.4 million, which also missed the Zacks Consensus Estimate of $104 million. The top line decreased almost 12.1% year over year due to the decrease in collaborative arrangements revenues related to the sole marketed drug, Linzess (linaclotide).
Quarter in Detail
As reported by partner AbbVie Inc. (ABBV - Free Report) , Ironwood’s marketed product — Linzess — generated net sales of $211.2 million in the United States, down 22% year over year, due to continued pricing pressure. However, total prescriptions for Linzess increased 11% year over year.
Ironwood and AbbVie equally share Linzess’ brand collaboration profits and losses.
IRWD’s share of net profit from the sales of Linzess in the United States (included in collaborative revenues) totaled $91.4 million, declining almost 12.8% year over year. Linzess share of profit was affected by the $30.0 million gross-to-net change in estimate, which was recorded in the first quarter of 2024.
Linzess’ collaborative revenues from U.S. sales missed our model estimate of $103.9 million.
Ironwood has agreements with two partners — Astellas Pharma and AstraZeneca (AZN - Free Report) — related to the development and commercialization of Linzess in Japan and China, respectively.
Both Astellas and AstraZeneca have exclusive rights to develop and market the drug in their respective territories. Astellas and AZN are liable to pay royalties to Ironwood on net Linzess revenues earned in their regions.
Ironwood recorded $3 million in royalties and other revenues, up 15.3% from the prior-year quarter’s figure.
Operating expenses (including research and development expenses, selling, general and administrative expenses and restructuring expenses) in the reported quarter were $69.4 million compared with $1.2 billion recorded in the year-ago quarter.
Operating expenses in the year-ago quarter included a one-time charge of $1.1 billion of acquired in-process research and development (“IPR&D”) from the acquisition of VectivBio.
As of Jun 30, 2024, Ironwood had cash and cash equivalents worth $105.5 million compared with $121.5 million as of Mar 31, 2024.
2024 Guidance
Owing to the continued pricing pressure for Linzess resulting from higher-than-expected Medicaid utilization trends, Ironwood lowered its revenue guidance for 2024.
The company now expects total revenues in the range of $350 million-$375 million for 2024 compared with the earlier projection of $405-$425 million. U.S. sales of Linzess are now expected in the range of $900-$950 million. Earlier, the company expected U.S. sales of Linzess to decline in the mid-single digit range in 2024.
In response to the lowered revenue guidance, IRWD stock declined 32.6% on Aug 8.
Shares of Ironwood have plunged 64.6% year to date compared with the industry’s decline of 5.2%.
Image Source: Zacks Investment Research
Meanwhile, the company now expects to deliver adjusted EBITDA of more than $75 million for 2024 versus the earlier projection of more than $120 million.
Pipeline Updates
With the acquisition of VectivBio last June, Ironwood acquired the rights to develop and commercialize apraglutide.
Ironwood is evaluating the safety and efficacy of once-weekly subcutaneous apraglutide in the pivotal phase III STARS study for reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF).
IRWD plans to complete a new drug application filing for apraglutide to the FDA for the treatment of adult patients with SBS who are dependent on PS in the first quarter of 2025.
Ironwood is developing two other pipeline candidates, IW-3300 and CNP-104.
A phase II proof-of-concept study is evaluating IW-3300 in a mid-stage study for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis.
Ironwood, in collaboration with COUR Pharmaceuticals, is developing CNP-104 for treating primary biliary cholangitis (PBC). The latter is evaluating CNP-104 in PBC patients, with top-line data from the same expected later in the third quarter of 2024.
Ironwood Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for Exact Sciences’ 2024 loss per share have narrowed from $1.09 to $1.00. Loss per share estimates for 2025 have narrowed from 21 cents to 8 cents. Year to date, shares of EXAS have decreased 22.6%.
EXAS’ earnings beat estimates in three of the trailing four quarters while meeting the same on the remaining occasion, the average surprise being 56.19%.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) reported break-even earnings for the second quarter of 2024 compared with the Zacks Consensus Estimate of earnings of 17 cents per share. The company had recorded adjusted earnings of 31 cents per share in the year-ago quarter.
Total revenues in the second quarter were $94.4 million, which also missed the Zacks Consensus Estimate of $104 million. The top line decreased almost 12.1% year over year due to the decrease in collaborative arrangements revenues related to the sole marketed drug, Linzess (linaclotide).
Quarter in Detail
As reported by partner AbbVie Inc. (ABBV - Free Report) , Ironwood’s marketed product — Linzess — generated net sales of $211.2 million in the United States, down 22% year over year, due to continued pricing pressure. However, total prescriptions for Linzess increased 11% year over year.
Ironwood and AbbVie equally share Linzess’ brand collaboration profits and losses.
IRWD’s share of net profit from the sales of Linzess in the United States (included in collaborative revenues) totaled $91.4 million, declining almost 12.8% year over year. Linzess share of profit was affected by the $30.0 million gross-to-net change in estimate, which was recorded in the first quarter of 2024.
Linzess’ collaborative revenues from U.S. sales missed our model estimate of $103.9 million.
Ironwood has agreements with two partners — Astellas Pharma and AstraZeneca (AZN - Free Report) — related to the development and commercialization of Linzess in Japan and China, respectively.
Both Astellas and AstraZeneca have exclusive rights to develop and market the drug in their respective territories. Astellas and AZN are liable to pay royalties to Ironwood on net Linzess revenues earned in their regions.
Ironwood recorded $3 million in royalties and other revenues, up 15.3% from the prior-year quarter’s figure.
Operating expenses (including research and development expenses, selling, general and administrative expenses and restructuring expenses) in the reported quarter were $69.4 million compared with $1.2 billion recorded in the year-ago quarter.
Operating expenses in the year-ago quarter included a one-time charge of $1.1 billion of acquired in-process research and development (“IPR&D”) from the acquisition of VectivBio.
As of Jun 30, 2024, Ironwood had cash and cash equivalents worth $105.5 million compared with $121.5 million as of Mar 31, 2024.
2024 Guidance
Owing to the continued pricing pressure for Linzess resulting from higher-than-expected Medicaid utilization trends, Ironwood lowered its revenue guidance for 2024.
The company now expects total revenues in the range of $350 million-$375 million for 2024 compared with the earlier projection of $405-$425 million. U.S. sales of Linzess are now expected in the range of $900-$950 million. Earlier, the company expected U.S. sales of Linzess to decline in the mid-single digit range in 2024.
In response to the lowered revenue guidance, IRWD stock declined 32.6% on Aug 8.
Shares of Ironwood have plunged 64.6% year to date compared with the industry’s decline of 5.2%.
Image Source: Zacks Investment Research
Meanwhile, the company now expects to deliver adjusted EBITDA of more than $75 million for 2024 versus the earlier projection of more than $120 million.
Pipeline Updates
With the acquisition of VectivBio last June, Ironwood acquired the rights to develop and commercialize apraglutide.
Ironwood is evaluating the safety and efficacy of once-weekly subcutaneous apraglutide in the pivotal phase III STARS study for reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF).
IRWD plans to complete a new drug application filing for apraglutide to the FDA for the treatment of adult patients with SBS who are dependent on PS in the first quarter of 2025.
Ironwood is developing two other pipeline candidates, IW-3300 and CNP-104.
A phase II proof-of-concept study is evaluating IW-3300 in a mid-stage study for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis.
Ironwood, in collaboration with COUR Pharmaceuticals, is developing CNP-104 for treating primary biliary cholangitis (PBC). The latter is evaluating CNP-104 in PBC patients, with top-line data from the same expected later in the third quarter of 2024.
Ironwood Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Ironwood Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Ironwood Pharmaceuticals, Inc. Quote
Zacks Rank & Stock to Consider
Ironwood currently carries a Zacks Rank #5 (Strong Sell).
A top-ranked stock in the healthcare sector is Exact Sciences Corporation (EXAS - Free Report) , sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Exact Sciences’ 2024 loss per share have narrowed from $1.09 to $1.00. Loss per share estimates for 2025 have narrowed from 21 cents to 8 cents. Year to date, shares of EXAS have decreased 22.6%.
EXAS’ earnings beat estimates in three of the trailing four quarters while meeting the same on the remaining occasion, the average surprise being 56.19%.